Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
04 June 2019 | Story Valentino Ndaba | Photo Charl Devenish
Prof Cathryn Tonne
Air pollution not only costs lives, it costs money too. Pictured is Prof Cathryn Tonne presenting a guest lecture on air pollution at the Bloemfontein Campus.

Health effects associated with ambient air pollution (AAP) have been well documented. Subsequently, the relationship between pollution and financial outcomes have also become a focus for case studies globally. An Environmental Research journal article revealed that “low and middle-income countries are disproportionately affected by the global burden of adverse health effects caused by AAP”. 

A high price to pay

In 2012, high concentrations of air pollution caused 7.4% of all deaths, costing South Africa up to 6% of its Gross Domestic Product. According to the recent International Growth Centre study conducted by senior University of Cape Town researchers, this is a direct consequence of the country’s heavy dependence of fossil fuels, a source of health-damaging air pollution and greenhouse pollutants.

Stunted human and economic growth

These South African statistics are attested to by Prof Cathryn Tonne who recently presented a guest lecture on air pollution which was hosted by the University of the Free State (UFS) Business School.

“Air pollution can affect economic development through several pathways, and health is an important one. Air pollution is linked to shorter life expectancy, chronic disease, asthma exacerbation and many other health outcomes that result in absenteeism from work and school. These have large direct costs to the health system.” 

Prof Tonne says that air pollution exposure in children is linked to reduced cognitive development, with important impacts on human capital. As a result, children are not reaching their full potential in terms of neurodevelopment, which has an effect on their income prospects and the economy as a whole. 

Resolving a looming disaster

Technology may be employed to radically clean the air. Cities need to lead in the reduction of air pollution by promoting renewable energy, using active transport such as walking or cycling, and investing in infrastructure to make this safe and attractive. 

With researchers playing a major role in strengthening the case for aggressive air pollution control, the government needs to implement policies in order to control sources of air pollution. This global health and economic issue also requires individuals and communities to play their part to improve air quality.

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept